Hillsdale Investment Management Inc. Has $295,000 Stake in Bioventus Inc. (NYSE:BVS)

Hillsdale Investment Management Inc. trimmed its position in shares of Bioventus Inc. (NYSE:BVS) by 9.9% during the 4th quarter, HoldingsChannel reports. The firm owned 28,092 shares of the company’s stock after selling 3,100 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Bioventus were worth $295,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BVS. HighTower Advisors LLC grew its holdings in shares of Bioventus by 11.3% during the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock valued at $143,000 after buying an additional 1,380 shares in the last quarter. Principal Financial Group Inc. boosted its position in Bioventus by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock worth $202,000 after acquiring an additional 1,652 shares during the period. Virtus Fund Advisers LLC purchased a new position in Bioventus during the 3rd quarter valued at about $42,000. Plato Investment Management Ltd acquired a new position in shares of Bioventus in the 4th quarter valued at about $38,000. Finally, Quest Partners LLC purchased a new stake in shares of Bioventus in the third quarter worth approximately $51,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bioventus

In other Bioventus news, CEO Robert E. Claypoole sold 28,786 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the transaction, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Mark Leonard Singleton sold 6,498 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the transaction, the chief financial officer now owns 118,817 shares in the company, valued at approximately $1,210,745.23. This trade represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,682 shares of company stock worth $382,725 in the last 90 days. 32.90% of the stock is owned by insiders.

Bioventus Trading Up 0.7 %

NYSE:BVS opened at $9.72 on Tuesday. The company has a market capitalization of $788.83 million, a P/E ratio of -15.93 and a beta of 0.86. The stock’s 50 day moving average price is $10.11 and its 200 day moving average price is $11.01. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BVS shares. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.